Shao Qun, Han Dongmei, Liu Danbo, Zheng Xiaoli, Dong Lei, Wang Zhidong, Ding Li, Yan Hongmin, Wang Hengxiang, Duan Lianning
Department of Hematology, the Air Force General Hospital of Anhui Medical College, Beijing 100142, China.
Zhonghua Xue Ye Xue Za Zhi. 2014 Jun;35(6):505-10. doi: 10.3760/cma.j.issn.0253-2727.2014.06.007.
To investigate the therapeutic effects of the conditioning regimen with busulfan plus cyclophosphamide (BU+CY) or total body irradiation plus cyclophosphamide (TBI+CY) on haploidentical stem cell transplantation (HSCT) in hematologic malignancy.
The clinical outcomes of 77 HSCT recipients with hematologic malignancy from January 2001 to December 2010, including 21 AML, 33 ALL, 19 CML and 4 MDS were retrospectively evaluated. Among them, 65 patients obtained complete remission (CR) and 12 non-remission (NR) before transplantation; 39 patients received conditioning regimen with BU+CY, and 38 with TBI+CY.
There were no statistically significant differences in hematopoietic reconstitution, disease free survival (DFS), and transplant- related mortality (TRM) between two groups. The estimated 3- years overall survival (OS) was 56.4% for BU+CY and 31.6% for TBI + CY (P=0.0283). The overall relapse rate was similar between two groups (15.4% vs 34.2%; P=0.1538). However, the accumulative probability of relapse at 1-year was significantly lower in BU+CY than that in TBI+CY group (2.56% vs 26.67%; P=0.0116). The incidence of grade II-IV graft-versus-host disease (GVHD) was similar between two regimens (20.5% in BU+CY group and 18.4% in TBI+CY group; P=0.8168). The incidence of chronic GVHD (cGVHD) was higher in the TBI+CY group than that of BU+CY group (84.6% vs 41.1%; P=0.0007). The extensive GVHD obtained the similar outcome (30.8% vs 10.5%; P=0.0416).
Patients using BU+CY as conditioning regimen before transplant could obtain a better 3 year OS and lower short-term relapse rate. The TBI+CY conditioning regimen could significantly increase the incidence of cGVHD without increasing the acute GVHD. BU+CY conditioning regimen could be used for HSCT, but the attention should be paid to prevent the related hemorrhagic cystitis.
探讨白消安加环磷酰胺(BU+CY)或全身照射加环磷酰胺(TBI+CY)预处理方案在血液系统恶性肿瘤单倍体造血干细胞移植(HSCT)中的治疗效果。
回顾性评估2001年1月至2010年12月期间77例血液系统恶性肿瘤HSCT受者的临床结局,其中急性髓系白血病(AML)21例、急性淋巴细胞白血病(ALL)33例、慢性髓系白血病(CML)19例、骨髓增生异常综合征(MDS)4例。其中,65例患者移植前获得完全缓解(CR),12例未缓解(NR);39例患者接受BU+CY预处理方案,38例接受TBI+CY预处理方案。
两组在造血重建、无病生存(DFS)和移植相关死亡率(TRM)方面无统计学显著差异。估计3年总生存(OS)率,BU+CY组为56.4%,TBI+CY组为31.6%(P=0.0283)。两组的总复发率相似(15.4%对34.2%;P=0.1538)。然而,BU+CY组1年时的累积复发概率显著低于TBI+CY组(2.56%对26.67%;P=0.0116)。两种预处理方案的II-IV级移植物抗宿主病(GVHD)发生率相似(BU+CY组为20.5%,TBI+CY组为18.4%;P=0.8168)。慢性GVHD(cGVHD)发生率TBI+CY组高于BU+CY组(84.6%对41.1%;P=0.0007)。广泛性GVHD的情况相似(30.8%对10.5%;P=0.0416)。
移植前采用BU+CY作为预处理方案的患者可获得更好的3年总生存率和更低的短期复发率。TBI+CY预处理方案可显著增加cGVHD的发生率,而不增加急性GVHD的发生率。BU+CY预处理方案可用于HSCT,但应注意预防相关出血性膀胱炎。